PMID: 8960104Oct 1, 1996Paper

Molecular diagnosis and monitoring of acute myeloid leukemia

Leukemia Research
A Biondi, A Rambaldi

Abstract

This concise review focuses on the new possibilities offered by molecular biology for the accurate diagnosis of chromosome abnormalities characteristic of some acute myeloid leukemias. Translocations t(8;21), t(15;17) and inv(16) may account for up to 30% of all cases of adult and childhood AML and their identification either by cytogenetics or molecular techniques is becoming of crucial importance for the routine diagnosis and treatment of AML, since they allow the identification of patients whose likelihood of cure is remarkably better. In these patients, the need of myeloablative protocols, supported by autologous or allogeneic transplantation, may not be required at least in first remission, and this can prevent the delivery of inappropriately toxic therapies. On the other hand, patients whose blasts are showing rearrangements of 11q23 band had a significantly worse prognosis and its precise identification may help the accrual to more appropriate and aggressive therapeutic protocols. These molecular markers are offering new tools, which are extremely sensitive, for the detection of minimal residual disease (MRD) for a growing number of AML patients. Although very promising in acute promyelocytic leukemia, the clinical signi...Continue Reading

References

Jun 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·M AlcalayP G Pelicci
Jul 15, 1989·Cancer Genetics and Cytogenetics·D C ArthurG W Dewald
Aug 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·E S KawasakiF P McCormick
Jun 1, 1995·Genes, Chromosomes & Cancer·O A Bernard, R Berger
Nov 10, 1994·Nature·T H Rabbitts
Feb 3, 1994·The New England Journal of Medicine·M J Cline
Jul 15, 1993·The New England Journal of Medicine·R P WarrellL Degos

❮ Previous
Next ❯

Citations

Dec 30, 2004·Cytometry. Part B, Clinical Cytometry·Claudia LangebrakeDirk Reinhardt
Sep 13, 2003·Cancer Letters·Orlev Levy-NissenbaumIsaac P Witz
May 30, 2001·Cancer Genetics and Cytogenetics·A V MoormanG J Morgan
Feb 17, 2006·European Journal of Haematology·P L J van der HeidenR M Y Barge
Feb 27, 2003·The Journal of Pharmacology and Experimental Therapeutics·HaiQing DaiWilliam F Elmquist
Feb 26, 2011·American Journal of Clinical Pathology·Sara A McClintock-TreepDavid R Head
May 11, 2011·British Journal of Haematology·Henrik Hasle, Charlotte M Niemeyer
Sep 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wolfgang R SperrPeter Valent
Aug 1, 1997·Disease-a-month : DM·P Jacobs

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.